NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)
$0.84
-0.0799 ( -8.65% ) 497.7K
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Market Data
Open
$0.84
Previous close
$0.92
Volume
497.7K
Market cap
$15.85M
Day range
$0.80 - $0.95
52 week range
$0.40 - $2.33
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 3 | Oct 02, 2023 |
6-k | Quarterly Reports | 1 | Sep 29, 2023 |
6-k | Quarterly Reports | 3 | Sep 20, 2023 |
6-k | Quarterly Reports | 3 | Sep 19, 2023 |
6-k | Quarterly Reports | 27 | Sep 12, 2023 |
6-k | Quarterly Reports | 51 | Aug 16, 2023 |
6-k | Quarterly Reports | 3 | Jul 06, 2023 |